The link between VLA-4 and JC virus reactivation

References

• Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J. Cell Sci.119(Pt 19), 3901–3903 (2006).
   PubMed Web of Science ®Google Scholar
• Byron A, Humphries JD, Askari JA et al. Anti-integrin monoclonal antibodies. J. Cell Sci.122(Pt 22), 4009–4011 (2009).
   PubMed Web of Science ®Google Scholar
• Bungartz G, Stiller S, Bauer M et al. Adult murine hematopoiesis can proceed without β1 and β7 integrins. Blood108(6), 1857–1864 (2006).
   PubMedGoogle Scholar
• Kinashi T. Integrin regulation of lymphocyte trafficking: lessons from structural and signaling studies. Adv. Immunol.93, 185–227 (2007).
   PubMedGoogle Scholar
• Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol.6(12), 1182–1190 (2005).
   PubMed Web of Science ®Google Scholar
• Stuve O, Gold R, Chan A et al. α4-Integrin antagonism with natalizumab: effects and adverse effects. J. Neurol.255(Suppl. 6), S58–S65 (2008).
   PubMed Web of Science ®Google Scholar
• Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J. Neurol. Sci.274(1–2), 23–26 (2008).
   PubMedGoogle Scholar
• Battistini L, Piccio L, Rossi B et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood101(12), 4775–4782 (2003).
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature356(6364), 63–66 (1992).
   PubMed Web of Science ®Google Scholar
• Stuve O, Kieseier BC, Hemmer B et al. Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch. Neurol.67(11), 1307–1315 (2010).
   PubMedGoogle Scholar
• del Pilar Martin M, Cravens PD, Winger R et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol.65(12), 1596–1603 (2008).
   PubMed Web of Science ®Google Scholar
• Imai Y, Shimaoka M, Kurokawa M. Essential roles of VLA-4 in the hematopoietic system. Int. J. Hematol.91(4), 569–575 (2010).
   PubMed Web of Science ®Google Scholar
• Bonig H, Wundes A, Chang KH, Lucas S. Papayannopoulou T, Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood111(7), 3439–3441 (2008).
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology71(17), 1350–1354 (2008).
   PubMed Web of Science ®Google Scholar
• Zohren F, Toutzaris D, Klarner V et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood111(7), 3893–3895 (2008).
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann. Rev. Med.61, 35–47 (2010).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis.199(6), 837–846 (2009).
   PubMed Web of Science ®Google Scholar
• Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog.5(3), e1000363 (2009).
   PubMed Web of Science ®Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf.33(11), 969–983 (2010).
   PubMed Web of Science ®Google Scholar
• Jensen PN, Major EO. Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. J. Leukoc. Biol.65(4), 428–438 (1999).
   PubMedGoogle Scholar
• Houff SA, Major EO, Katz DA et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N. Engl. J. Med.318(5), 301–305 (1988).
   PubMed Web of Science ®Google Scholar
• Engsig FN, Hansen AB, Omland LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis.199(1), 77–83 (2009).
   PubMed Web of Science ®Google Scholar
• Khanna N, Elzi L, Mueller NJ et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study. Clin. Infect. Dis.48(10), 1459–1466 (2009).
   PubMed Web of Science ®Google Scholar
• Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiat.81(11), 1288–1291 (2010).
   PubMed Web of Science ®Google Scholar
• Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann. Neurol.60(2), 162–173 (2006).
   PubMed Web of Science ®Google Scholar
• Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin. Neurol.19(2), 193–200 (1999).
   PubMed Web of Science ®Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol.9(4), 425–437 (2010).
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on adverse drug events and reports (RADAR) project. Lancet Oncol.10(8), 816–824 (2009).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 911–923 (2006).
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol.59(5), 743–747 (2006).
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Bar-Or A et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol.63(10), 1383–1387 (2006).
   PubMed Web of Science ®Google Scholar
• Niino M, Bodner C, Simard ML et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol.59(5), 748–754 (2006).
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med.353(4), 369–374 (2005).
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med.353(4), 375–381 (2005).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353(4), 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology71(5), 357–364 (2008).
   PubMed Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol.9(4), 438–446 (2010).
   PubMed Web of Science ®Google Scholar
• Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann. Neurol.64(4), 379–387 (2008).
   PubMed Web of Science ®Google Scholar
• Tan CS, Ellis LC, Wuthrich C et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J. Virol.84(18), 9200–9209 (2010).
   PubMed Web of Science ®Google Scholar
• White FA III, Ishaq M, Stoner GL, Frisque RJ. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J. Virol.66(10), 5726–5734 (1992).
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol.70(10), 7004–7012 (1996).
   PubMed Web of Science ®Google Scholar
• Chen Y, Bord E, Tompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med.361(11), 1067–1074 (2009).
   PubMed Web of Science ®Google Scholar
• Warnke C, Smolianov V, Dehmel T et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult. Scler.17(2), 151–156 (2011).
   PubMedGoogle Scholar
• Slobedman B, Cao JZ, Avdic S et al. Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiol.5(6), 883–900 (2010).
   PubMedGoogle Scholar
• Chapagain ML, Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J. Infect. Dis.202(2), 184–191 (2010).
   PubMed Web of Science ®Google Scholar
• Marzocchetti A, Wuthrich C, Tan CS et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J. Neurovirol.14(5), 455–458 (2008).
   PubMed Web of Science ®Google Scholar
• Tan CS, Dezube BJ, Bhargava P et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J. Infect. Dis.199(6), 881–888 (2009).
   PubMed Web of Science ®Google Scholar
• Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J. Neuroimmunol.194(1–2), 153–164 (2008).
   PubMed Web of Science ®Google Scholar
• Marshall LJ, Dunham L, Major EO. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J. Gen. Virol.91(Pt 12), 3042–3052 (2010).
   PubMedGoogle Scholar
• Houff SA, Berger J. The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein–Barr virus-transformed B cells point to an important feature of JC virus biology? J. Infect. Dis.202(2), 181–183 (2010).
   PubMedGoogle Scholar
• Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann. Neurol.68(3), 384–391 (2010).
   PubMedGoogle Scholar
• Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MABS1(6), 583–589 (2009).
   PubMed Web of Science ®Google Scholar
• Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology72(17), 1458–1464 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr. Opin. Neurol.24(3), 284–290 (2011).
   PubMedGoogle Scholar
• Linda H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med.361(11), 1081–1087 (2009).
   PubMed Web of Science ®Google Scholar
• Wenning W, Haghikia A, Laubenberger J et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med.361(11), 1075–1080 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann. NY Acad. Sci.1184, 106–120 (2010).
   PubMed Web of Science ®Google Scholar
• Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol.68(2), 186–191 (2011).
   PubMedGoogle Scholar
• McCombe JA, Auer RN, Maingat FG et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology72(9), 835–841 (2009).
   PubMed Web of Science ®Google Scholar
• McCarthy M, Nath A. Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). Curr. Neurol. Neurosci. Rep.10(6), 467–475 (2010).
   PubMedGoogle Scholar
• Muller M, Wandel S, Colebunders R et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis.10(4), 251–261 (2010).
   PubMed Web of Science ®Google Scholar
• Marshall LJ, Major EO. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J. Neuroimmune Pharmacol.5(3), 404–417 (2010).
   PubMedGoogle Scholar
• Neu U, Stehle T, Atwood WJ. The polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry. Virology384(2), 389–399 (2009).
   PubMed Web of Science ®Google Scholar
• Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch. Neurol.66(2), 255–258 (2009).
   PubMed Web of Science ®Google Scholar
• Verma S, Cikurel K, Koralnik IJ et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J. Infect. Dis.196(5), 709–711 (2007).
   PubMed Web of Science ®Google Scholar
• Marzocchetti A, Tompkins T, Clifford DB et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology73(19), 1551–1558 (2009).
   PubMed Web of Science ®Google Scholar
• Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology364(1), 55–63 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang ZG, Cohen J, Marshall LJ, Major EO. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob. Agents Chemother.54(11), 4723–4732 (2010).
   PubMed Web of Science ®Google Scholar
• Gosert R, Rinaldo CH, Wernli M, Major EO, Hirsch HH. CMX001 (1-O-Hexadecyloxypropyl-Cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob. Agents Chemother.55(5), 2129–2136 (2011).
   PubMed Web of Science ®Google Scholar
• Kivisakk P, Healy BC, Viglietta V et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology72(22), 1922–1930 (2009).
   PubMed Web of Science ®Google Scholar
• Coisne C, Mao W, Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J. Immunol.182(10), 5909–5913 (2009).
   PubMed Web of Science ®Google Scholar
• Major EO. Reemergence of PML in natalizumab-treated patients – new cases, same concerns. N. Engl. J. Med.361(11), 1041–1043 (2009).
   PubMedGoogle Scholar
• Khanna N, Wolbers M, Mueller NJ et al. JC virus-specific immune responses in human immunodeficiency virus Type 1 patients with progressive multifocal leukoencephalopathy. J. Virol.83(9), 4404–4411 (2009).
   PubMed Web of Science ®Google Scholar
• Gheuens S, Bord E, Kesari S et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML-IRIS. J. Virol.85(14), 7256–7263 (2011).
   PubMed Web of Science ®Google Scholar
• Weber F, Goldmann C, Kramer M et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann. Neurol.49(5), 636–642 (2001).
   PubMed Web of Science ®Google Scholar
• Khademi M, Bornsen L, Rafatnia F et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur. J. Neurol.16(4), 528–536 (2009).
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol.68(3), 295–303 (2010).
   PubMed Web of Science ®Google Scholar
• Goelz SE, Gorelik L, Subramanyam M. Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann. Neurol.69(2), 429–430; author reply 430–421 (2011).
   PubMedGoogle Scholar
• Brooks DG, Walsh KB, Elsaesser H, Oldstone MB. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc. Natl Acad. Sci. USA107(7), 3018–3023 (2010).
   PubMed Web of Science ®Google Scholar
• Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol.6(10), 887–902 (2007).
   PubMed Web of Science ®Google Scholar
• Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch. Neurol.66(1), 54–59 (2009).
   PubMed Web of Science ®Google Scholar
• Chabas D, Ness J, Belman A et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology74(5), 399–405 (2010).
   PubMed Web of Science ®Google Scholar
• Pohl D, Waubant E, Banwell B et al. Treatment of pediatric multiple sclerosis and variants. Neurology68(16 Suppl. 2), S54–S65 (2007).
   Web of Science ®Google Scholar
• Kuntz NL, Chabas D, Weinstock-Guttman B et al. Treatment of multiple sclerosis in children and adolescents. Exp. Opin. Pharmacother.11(4), 505–520 (2010).
   PubMed Web of Science ®Google Scholar
• Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur. J. Paediatr. Neurol.13(1), 67–71 (2009).
   PubMed Web of Science ®Google Scholar
• Huppke P, Stark W, Zurcher C et al. Natalizumab use in pediatric multiple sclerosis. Arch. Neurol.65(12), 1655–1658 (2008).
   PubMed Web of Science ®Google Scholar
• Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther. Adv. Neurol. Disord.3(5), 293–299 (2010).
   PubMedGoogle Scholar
• Yeh EA, Chitnis T, Krupp L et al. Pediatric multiple sclerosis. Nat. Rev. Neurol.5(11), 621–631 (2009).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology74(Suppl. 1), S31–S40 (2010).
   PubMed Web of Science ®Google Scholar
• Fontoura P. Monoclonal antibody therapy in multiple sclerosis: paradigm shifts and emerging challenges. MABS2(6), 670–681 (2010).
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med.146(1), 25–33 (2007).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med.358(7), 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Ng KP, Cambridge G, Leandro MJ et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis.66(9), 1259–1262 (2007).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum.60(11), 3225–3228 (2009).
   PubMed Web of Science ®Google Scholar
• Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol.68(9), 1156–164 (2011).
   PubMed Web of Science ®Google Scholar
• Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum.54(8), 2377–2386 (2006).
   PubMed Web of Science ®Google Scholar
• Berger JR, Houff S. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol. Res.28(3), 299–305 (2006).
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood113(20), 4834–4840 (2009).
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, LaPlant BR et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res.32(12), 1849–1856 (2008).
   PubMed Web of Science ®Google Scholar
• Keene DL, Legare C, Taylor E et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can. J. Neurol. Sci.38(4), 565–571 (2011).
   PubMed Web of Science ®Google Scholar
• Kothary N, Diak IL, Brinker A et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J. Am. Acad. Dermatol.65(3), 546–551 (2011).
   PubMed Web of Science ®Google Scholar